148 related articles for article (PubMed ID: 36912809)
1. Prognostic Awareness, Palliative Care Use, and Barriers to Palliative Care in Patients Undergoing Immunotherapy or Chemo-Immunotherapy for Metastatic Lung Cancer.
McLouth LE; Gabbard J; Levine BJ; Golden SL; Lycan TW; Petty WJ; Weaver KE
J Palliat Med; 2023 Jun; 26(6):831-836. PubMed ID: 36912809
[No Abstract] [Full Text] [Related]
2. Fostering efficacy of anti-PD-1-treatment: Nivolumab plus radiotherapy in advanced non-small cell lung cancer - study protocol of the FORCE trial.
Bozorgmehr F; Hommertgen A; Krisam J; Lasitschka F; Kuon J; Maenz M; Huber PE; König L; Kieser M; Debus J; Thomas M; Rieken S
BMC Cancer; 2019 Nov; 19(1):1074. PubMed ID: 31703637
[TBL] [Abstract][Full Text] [Related]
3. Outpatient palliative care and thoracic medical oncology: Referral criteria and clinical care pathways.
Caraceni A; Lo Dico S; Zecca E; Brunelli C; Bracchi P; Mariani L; Garassino MC; Vitali M
Lung Cancer; 2020 Jan; 139():13-17. PubMed ID: 31704278
[TBL] [Abstract][Full Text] [Related]
4. Benefit of ablative versus palliative-only radiotherapy in combination with nivolumab in patients affected by metastatic kidney and lung cancer.
Desideri I; Francolini G; Scotti V; Pezzulla D; Becherini C; Terziani F; Delli Paoli C; Olmetto E; Visani L; Meattini I; Greto D; Bonomo P; Loi M; Detti B; Livi L
Clin Transl Oncol; 2019 Jul; 21(7):933-938. PubMed ID: 30565084
[TBL] [Abstract][Full Text] [Related]
5. Utilization pattern and service settings of palliative care for patients with metastatic non-small cell lung cancer.
Huo J; Hong YR; Turner K; Bian J; Grewal R; Wilkie DJ
Cancer; 2019 Dec; 125(24):4481-4489. PubMed ID: 31449674
[TBL] [Abstract][Full Text] [Related]
6. Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.
Bodd MH; Locke SC; Wolf SP; Antonia S; Crawford J; Hartman J; Herring KW; Ready NE; Stinchcombe TE; Troy JD; Williams C; Clarke JM; LeBlanc TW
Lung Cancer; 2023 Jan; 175():17-26. PubMed ID: 36442383
[TBL] [Abstract][Full Text] [Related]
7. [Lung cancer : What has been confirmed in therapy?].
Heigener DF; Reck M
Internist (Berl); 2017 Dec; 58(12):1258-1263. PubMed ID: 29043377
[TBL] [Abstract][Full Text] [Related]
8. Components of early outpatient palliative care consultation in patients with metastatic nonsmall cell lung cancer.
Jacobsen J; Jackson V; Dahlin C; Greer J; Perez-Cruz P; Billings JA; Pirl W; Temel J
J Palliat Med; 2011 Apr; 14(4):459-64. PubMed ID: 21417739
[TBL] [Abstract][Full Text] [Related]
9. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval.
Khozin S; Carson KR; Zhi J; Tucker M; Lee SE; Light DE; Curtis MD; Bralic M; Kaganman I; Gossai A; Hofmeister P; Torres AZ; Miksad RA; Blumenthal GM; Pazdur R; Abernethy AP
Oncologist; 2019 May; 24(5):648-656. PubMed ID: 30591549
[TBL] [Abstract][Full Text] [Related]
10. Palliative care units in lung cancer in the real-world setting: a single institution's experience and its implications.
Masel EK; Schur S; Nemecek R; Mayrhofer M; Huber P; Adamidis F; Maehr B; Unseld M; Watzke HH; Pirker R
Ann Palliat Med; 2017 Jan; 6(1):6-13. PubMed ID: 27701880
[TBL] [Abstract][Full Text] [Related]
11. Patient-Reported Outcomes From Patients Receiving Immunotherapy or Chemoimmunotherapy for Metastatic Non-Small-Cell Lung Cancer in Clinical Practice.
Steffen McLouth LE; Lycan TW; Levine BJ; Gabbard J; Ruiz J; Farris M; Grant SC; Pajewski NM; Weaver KE; Petty WJ
Clin Lung Cancer; 2020 May; 21(3):255-263.e4. PubMed ID: 31917067
[TBL] [Abstract][Full Text] [Related]
12. Host immune-inflammatory markers to unravel the heterogeneous outcome and assessment of patients with PD-L1 ≥50% metastatic non-small cell lung cancer and poor performance status receiving first-line immunotherapy.
Banna GL; Tiseo M; Cortinovis DL; Facchinetti F; Aerts JGJV; Baldessari C; Giusti R; Bria E; Grossi F; Berardi R; Morabito A; Catino A; Genova C; Mazzoni F; Gelibter A; Rastelli F; Macerelli M; Chiari R; Gori S; Mansueto G; Citarella F; Cantini L; Rijavec E; Bertolini F; Cappuzzo F; De Toma A; Friedlaender A; Metro G; Pensieri MV; Porzio G; Ficorella C; Pinato DJ; Cortellini A; Addeo A
Thorac Cancer; 2022 Feb; 13(3):483-488. PubMed ID: 34939342
[TBL] [Abstract][Full Text] [Related]
13. Early palliative intervention for patients with advanced cancer.
Otsuka M; Koyama A; Matsuoka H; Niki M; Makimura C; Sakamoto R; Sakai K; Fukuoka M
Jpn J Clin Oncol; 2013 Aug; 43(8):788-94. PubMed ID: 23737605
[TBL] [Abstract][Full Text] [Related]
14. Digital Monitoring and Management of Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Treated With Cancer Immunotherapy and Its Impact on Quality of Clinical Care: Interview and Survey Study Among Health Care Professionals and Patients.
Schmalz O; Jacob C; Ammann J; Liss B; Iivanainen S; Kammermann M; Koivunen J; Klein A; Popescu RA
J Med Internet Res; 2020 Dec; 22(12):e18655. PubMed ID: 33346738
[TBL] [Abstract][Full Text] [Related]
15. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.
Greer JA; Pirl WF; Jackson VA; Muzikansky A; Lennes IT; Heist RS; Gallagher ER; Temel JS
J Clin Oncol; 2012 Feb; 30(4):394-400. PubMed ID: 22203758
[TBL] [Abstract][Full Text] [Related]
16. Palliative Thoracic Radiotherapy for Non-small Cell Lung Cancer: Is There any Impact of Target Volume Size on Survival?
Nieder C; Imingen KS; Mannsaker B; Yobuta R
Anticancer Res; 2021 Jan; 41(1):355-358. PubMed ID: 33419831
[TBL] [Abstract][Full Text] [Related]
17. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Ricciuti B; Dahlberg SE; Adeni A; Sholl LM; Nishino M; Awad MM
J Clin Oncol; 2019 Aug; 37(22):1927-1934. PubMed ID: 31206316
[TBL] [Abstract][Full Text] [Related]
18. Prior or concurrent radiotherapy and nivolumab immunotherapy in non-small cell lung cancer.
Ratnayake G; Shanker M; Roberts K; Mason R; Hughes BGM; Lwin Z; Jain V; O'Byrne K; Lehman M; Chua B
Asia Pac J Clin Oncol; 2020 Feb; 16(1):56-62. PubMed ID: 31721446
[TBL] [Abstract][Full Text] [Related]
19. Symptom improvement as prognostic factor for survival in cancer patients undergoing palliative care: a pilot study.
Narducci F; Grande R; Mentuccia L; Trapasso T; Sperduti I; Magnolfi E; Fariello AM; Gemma D; Gamucci T
Support Care Cancer; 2012 Jun; 20(6):1221-6. PubMed ID: 21688165
[TBL] [Abstract][Full Text] [Related]
20. Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval.
Khozin S; Abernethy AP; Nussbaum NC; Zhi J; Curtis MD; Tucker M; Lee SE; Light DE; Gossai A; Sorg RA; Torres AZ; Patel P; Blumenthal GM; Pazdur R
Oncologist; 2018 Mar; 23(3):328-336. PubMed ID: 29317551
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
